Form 4: Skye Bioscience Executive Receives Stock Options and Restricted Stock Units

Tuan Tu Diep, Chief Development Officer of Skye Bioscience, was granted stock options and restricted stock units (RSUs) tied to market capitalization and stock price milestones.

Summary

• Tuan Tu Diep, the Chief Development Officer of Skye Bioscience, received 75,000 stock options with an exercise price of $14.56, vesting monthly over four years starting February 29, 2024, and expiring on March 1, 2034.
• He also received 25,000 restricted stock units (RSUs) that vest upon achieving specific market capitalization and stock price targets.
• The vesting schedule for the RSUs is as follows: 25% upon reaching a $750 million market cap and $20.00 stock price, another 25% upon reaching a $1 billion market cap and $25.00 stock price, another 25% upon reaching a $1.25 billion market cap and $30.00 stock price, and the final 25% upon reaching a $1.5 billion or greater market cap and $35.00 stock price.
• No RSUs will vest until the compensation committee determines that shares can be sold to cover withholding tax obligations.
• Both the stock options and RSUs will fully vest upon a change in control of Skye Bioscience.
• Following these transactions, Diep directly owns 101,833 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice. The vesting conditions tied to market cap and stock price suggest a positive outlook for the company's growth, but the document itself is neutral in tone.

Positives

• The vesting of RSUs is tied to ambitious market capitalization and stock price targets, potentially aligning executive incentives with shareholder value creation.
• The four-year vesting schedule for the stock options encourages long-term commitment from the Chief Development Officer.
• The full vesting upon a change in control provides additional incentive for the executive to act in the best interests of shareholders during potential acquisition scenarios.

Risks

• The vesting of RSUs is contingent on achieving specific market capitalization and stock price targets, which may not be realized.
• The compensation committee's discretion to delay RSU vesting until shares can be sold to cover withholding tax obligations could potentially delay the executive's access to the shares.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of RSUs is tied to achieving significant market capitalization and stock price milestones, suggesting an expectation of future growth.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The specific vesting terms, tied to market capitalization and stock price, are designed to reward executives for driving company growth and increasing shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedules and performance-based milestones for RSUs are comparable to those used by other biotech companies to incentivize long-term growth and value creation.
• For example, companies like Vertex Pharmaceuticals and Regeneron Pharmaceuticals often use similar market capitalization and stock price targets in their RSU programs.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively, as they align executive incentives with shareholder value creation.
• Employees may be motivated by the potential for the company to achieve the market capitalization and stock price targets required for RSU vesting.

Key Dates